Royce & Associates LP reduced its stake in Zafgen, Inc. (NASDAQ:ZFGN) by 12.8% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 332,491 shares of the biopharmaceutical company’s stock after selling 49,000 shares during the quarter. Royce & Associates LP owned about 1.21% of Zafgen worth $1,167,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the company. Bank of New York Mellon Corp lifted its position in shares of Zafgen by 5.9% in the first quarter. Bank of New York Mellon Corp now owns 104,199 shares of the biopharmaceutical company’s stock valued at $485,000 after acquiring an additional 5,794 shares in the last quarter. Parametric Portfolio Associates LLC lifted its position in Zafgen by 55.8% during the first quarter. Parametric Portfolio Associates LLC now owns 28,832 shares of the biopharmaceutical company’s stock worth $134,000 after buying an additional 10,327 shares during the period. Paloma Partners Management Co lifted its position in Zafgen by 17.4% during the first quarter. Paloma Partners Management Co now owns 130,000 shares of the biopharmaceutical company’s stock worth $606,000 after buying an additional 19,278 shares during the period. Algert Global LLC purchased a new position in Zafgen during the second quarter worth about $123,000. Finally, Wells Fargo & Company MN lifted its position in Zafgen by 1,290.3% during the first quarter. Wells Fargo & Company MN now owns 43,531 shares of the biopharmaceutical company’s stock worth $203,000 after buying an additional 40,400 shares during the period. Institutional investors and hedge funds own 48.52% of the company’s stock.

Several equities analysts recently weighed in on ZFGN shares. ValuEngine downgraded Zafgen from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. Zacks Investment Research upgraded Zafgen from a “hold” rating to a “buy” rating and set a $4.00 target price on the stock in a research report on Saturday, July 8th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and one has given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $6.38.

In other Zafgen news, insider Dennis D. Kim purchased 10,000 shares of the stock in a transaction dated Tuesday, July 11th. The shares were acquired at an average price of $3.39 per share, for a total transaction of $33,900.00. Following the completion of the acquisition, the insider now owns 21,443 shares of the company’s stock, valued at approximately $72,691.77. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 21.20% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of US & international trademark and copyright law. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/09/16/royce-associates-lp-sells-49000-shares-of-zafgen-inc-zfgn.html.

Zafgen, Inc. (ZFGN) opened at 3.37 on Friday. The company’s 50-day moving average price is $3.45 and its 200 day moving average price is $3.98. Zafgen, Inc. has a 52-week low of $2.89 and a 52-week high of $5.46. The stock’s market capitalization is $92.62 million.

Zafgen (NASDAQ:ZFGN) last issued its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.49) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.03. During the same period in the previous year, the company posted ($0.55) EPS. On average, equities research analysts anticipate that Zafgen, Inc. will post ($2.23) earnings per share for the current year.

Zafgen Company Profile

Zafgen, Inc is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.

Want to see what other hedge funds are holding ZFGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zafgen, Inc. (NASDAQ:ZFGN).

Institutional Ownership by Quarter for Zafgen (NASDAQ:ZFGN)

Receive News & Stock Ratings for Zafgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen Inc. and related stocks with our FREE daily email newsletter.